Wire · opportunities
Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
The Barbara Ann Karmanos Cancer Institute is now offering FDA-approved daraxonrasib (Rasonque) for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are ineligible for combination chemotherapy, based on positive results from the phase III RASolute 302 trial.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You now can offer patients a newly approved targeted therapy that extends survival in advanced pancreatic cancer where chemotherapy options failed or are not viable. Quickly update treatment protocols to include daraxonrasib and prepare to manage patient discussions on its benefits and risks.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Topics